U.S. Law Firms Rally Investors for Legal Battle Against Novo Nordisk
A coalition of prominent U.S. securities law firms is mobilizing investors for a potential class-action lawsuit against Novo Nordisk (NVO). Over 20 firms, including Faruqi & Faruqi and Glancy Prongay & Murray, allege the pharmaceutical giant misled shareholders about risks related to GLP-1 compounding between May 7 and July 28, 2025.
The lawsuits claim Novo Nordisk systematically underestimated regulatory challenges while overestimating its capacity to transition patients from compounded drugs. Investors who purchased NVO securities during this period face a September 30, 2025 deadline to join the action.